BioRestorative Therapies, Inc. · NASDAQ:BRTX

BioRestorative Therapies — Investor Presentation (August 2023)

23 slides from BioRestorative Therapies's investor presentation, August 2023

  1. Slide 1: BioRestorative Therapies

    Rectorate therapies ——=pf Nasdaq of Nasdaq Company aN 40 Marcus Drive, Melville, 11747 NY 1 www.biorestorative.com

  2. Slide 2: Forward Looking Statement

    FORWARD LOOKING STATEMENT STATEMENTS IN THIS PRESENTATION, INCLUDING THE INFORMATION SET FORTH AS TO THE FUTURE FINANCIAL OR OPERATING PERFORMANCE OF BIORESTORATIVE THERAPIES, INC. (THE “COMPANY”) THAT ARE NOT CURRENT OR HISTORICAL FACTUAL STATEMENTS MAY CONSTITUTE “FORWARD LOOKING” INFORMATION WITH

  3. Slide 3: Leadership

    LEADERSHIP LANCE ALSTODT ROBERT KRISTAL FRANCISCO SILVA BOB PACCASASSI Chairman & CEO Chief Financial Officer Vice President of R&D Vice President of Quality Lance leads BRTX’s mission to Robert has a versatile Francisco has over 20 years of Robert has over 25 years of improve the lives of patients

  4. Slide 4: BRTX Company Overview

    BRTX COMPANY OVERVIEW Emerging Growth Publicly Traded Two platform technologies within Each Platform has multiple Nasdaq Listed Cell Therapy multi-billion dollar markets applications to leverage Company Musculoskeletal Health – Active Strong Financial Position with a Metabolic Disease – Key Strategi

  5. Slide 5: A Platform Technology

    A Platform Technology Preclinical Phase 1 Phase 2 Phase 3 Spine • Lumbar Autologous • Cervical • Thoracic Musculoskeletal System • Hips/Knees • Extremities • Avascular Zones Metabolic • Type 2 Diabetes • Obesity Allogeneic • PCOS Brown Adipose Stem Cells • ARDS • Long Hauler Covid Gene Modification

  6. Slide 6: Chronic Lumbar Disc Disease Program – Phase 2

    CHRONIC LUMBAR DISC DISEASE PROGRAM – PHASE 2  Lead investigational therapeutic product  Autologous (patient’s own) cell-based biologic  Hypoxic (low oxygen) cultured, bone marrow-derived  Single intradiscal injection – anticipated 30 minute in-office procedure DISC/SPINE  Prior human data prov

  7. Slide 7: Market Opportunity – BRTX-100

    MARKET OPPORTUNITY – BRTX 100 258 MILLION American adult population 64.5 MILLION American adults with chronic lower back pain prevalence 32 MILLION American adults with diagnosed and treated disc degeneration 15 MILLION Americans have pain caused by a protruding or injured disc 2.5 MILLION Invasive

  8. Slide 8: Standard of Care: Clinical and Economic Problem

    STANDARD OF CARE: CLINICAL AND ECONOMIC PROBLEM CONSERVATIVE TREATMENTS SURGICAL TREATMENTS OFTEN RECURRENT WITH RE-OP RATES OFTEN 10-20% ORAL MEDICATION TREATMENT/OPIOIDS SIMPLE ELEGANT SOLUTION SPINAL FUSION SURGERY INTRODUCE HYPOXIC CULTURED $1,000 - $2,000 Annually AUTOLOGOUS MSCs $110,000 1, 5

  9. Slide 9: Logistical/Clinical Process

    LOGISTICAL/CLINICAL PROCESS Shipping 3 Shipping 1 Cryoport 5 Cryoport BRTX-100® . Intradiscal delivery Bone marrow and blood Manufactured, and of BRTX-100® collected from subject QC released Sample shipped at ambient to BRTX-100® shipped BioRestorative frozen to clinical Therapies site Clinical Site

  10. Slide 10: Cleared DSMB June 2023

    CLEARED DSMB June 2023 • Unanimous approval by the DSMB to continue trial without changes • BRTX-100 is safe and well tolerated • All 4 subjects successfully dosed with either 40 mil hMSCs or placebo • First time 40 million cells injected in a human subject • 3:1 randomization • No Significant Adver

  11. Slide 11: Positive Human Data

    POSITIVE HUMAN DATA Human data from studies of therapies similar to brtx-100 show reduced pain, increased function, and an absence of significant safety issues with a durable response. 11

  12. Slide 12: Trial Design

    TRIAL DESIGN FDA Cleared IND 17275: Phase 2 Randomized, Controlled Study Design in Patients with CLDD Study Design and Patient Population  Study includes 99 subjects (2:1 product to placebo)  40.000.000 cells/dose  Included subjects will have only one symptomatic diseased disc  Primary efficacy

  13. Slide 13: Competitive Landscape / Key Differentiating Factors

    COMPETITIVE LANDSCAPE KEY DIFFERENTIATING FACTORS KEY ATTRIBUTES BRTX-100 ADVANTAGES: Normoxic cultured –  Autologous cells means low to no risk of rejection, Hypoxic cultured – in low with normal oxygen greater safety profile (introduction of viral/genetic), oxygen environment (5%) environment (~2

  14. Slide 14: BioRestorative Therapy Programs

    BIORESTORATIVE THERAPY PROGRAMS Metabolic Program ThermoStem Program  “Off the shelf” allogeneic cell-based therapy targeted to treat obesity, Type 2 diabetes and metabolic disorders using brown fat  stem cells  Brown fat has been shown to regulate metabolic homeostasis in the body  Large librar

  15. Slide 15: Metabolic Program Highlights

    METABOLIC PROGRAM HIGHLIGHTS First human stem cell derived BAT transfer White Fat Creation of first human 3D engineered artificial brown adipose tissue construct (aBAT) Successful delivery of 3D aBAT construct in mouse model Beige Fat Transplantation of aBAT lowered blood glucose levels Transplantat

  16. Slide 16: Metabolic Program Clinical Timeline

    METABOLIC PROGRAM CLINICAL TIMELINE 2023 2023 2024 Pre-IND Initiate File DMF Meeting Phase 1/2 with FDA with FDA Clinical Trial Expected filing a Drug Master File (“DMF”) with the FDA to facilitate licensing opportunities Schedule pre-IND (Investigational New Drug) meeting with FDA to discuss first-

  17. Slide 17: Intellectual Property

    INTELLECTUAL PROPERTY PROGRAM: PROGRAM: DISC/SPINE METABOLIC (THERMOSTEM) PATENT TITLES PATENT TITLES • Methods and Compositions to facilitate repair • Brown Fat Compositions and Methods of avascular tissue • Human Brown Adipose Derived Stem Cells and Uses • Surgical Methods and Compositions to • No

  18. Slide 18: 2023 Accomplishments

    2023 ACCOMPLISHMENTS  Expanded Thermostem patent portfolio in US and Japan  Two Notice of Allowances  Completed 4 patient Safety Run-in component for Phase 2  Announced a filing and execution of an ATM  Announced Northwell Healthcare Partnership – Largest Healthcare System in the Northeast  Cl

  19. Slide 19: Scientific Advisory Board

    SCIENTIFIC ADVISORY BOARD Wayne Marasco, M.D., Ph.D. is a principal faculty member of Harvard Stem Cell Institute as well as a WAYNE MARASCO, MD, PhD Professor in the Department of Cancer Immunology & AIDS at the Dana-Farber Cancer Institute and Chairman of SAB a Professor of Medicine at Harvard Med

  20. Slide 20: Company Highlights

    COMPANY HIGHLIGHTS  cGMP ISO-7 Certified Clean room  Disruptive Platform Technologies in Cellular Therapy  Strong Preliminary Data Indicative of Positive Trial Outcomes  Active Phase 2 Trial in Spine  Addressing Multi-Billion Dollar Markets with Unmet Needs  Opportunity for Key Strategic Partn

  21. Slide 21: Financial Summary

    FINANCIAL SUMMARY Current Capitalization Shares Basic Shares Outstanding 4,667,641 Cash 13 MILLION Debt $0 Data as Q2 filing 08/11/2023 21

  22. Slide 22: Upcoming Milestones/Catalysts

    BioRestorative Upcoming Milestones/Catalysts Events Timing Outcome Site Enrollment Announcements Ongoing • Continue to announce p0restigious sites and notable KOLs for BRTX 100 enrollment Patient Recruitment/Enrollment • Periodically update for meaningful enrollment milestones • Additional patents a

  23. Slide 23: BioRestorative Therapies

    porectonaive therapies

BioRestorative Therapies — Investor Presentation (August 2023) on 6ix